Smad2 isoforms are differentially expressed during mouse brain development and aging

International Journal of Developmental Neuroscience

Volumn 27, Issue 5, 2009, Pages 501-510

  Ueberham, Uwe ^a,b   Lange, Peggy ^a   Ueberham, Elke ^a,b   Brückner, Martina K ^a   Hartlage Rübsamen, Maike ^a   Pannicke, Thomas ^a   Rohn, Susanne ^a   Cross, Michael ^a   Arendt, Thomas ^a,b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Aging; Brain development; Isoform; Smad2; Splicing

Indexed keywords

ISOPROTEIN; SMAD2 PROTEIN;

AGING; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN DEVELOPMENT; CELL FRACTIONATION; CELL NUCLEUS; CONTROLLED STUDY; EMBRYO; EXON; MOUSE; NERVE CELL DIFFERENTIATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

AGING; ALTERNATIVE SPLICING; ANIMALS; BRAIN; CELLS, CULTURED; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; NEURONS; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMAD2 PROTEIN; SUBCELLULAR FRACTIONS;

EID: 67349117098     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2009.04.001     Document Type: Article

References (39)

1. Carlson M.E., Hsu M., and Conboy I.M. Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature 454 (2008) 528-532
2. Chalmers K.A., and Love S. Neurofibrillary tangles may interfere with smad 2/3 signaling in neurons. J. Neuropathol. Exp. Neurol. 66 (2007) 158-167
3. Chalmers K.A., and Love S. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies. J. Neuropathol. Exp. Neurol. 66 (2007) 1019-1026
4. Chen Z., Smithberger J., Sun B., and Eggerman T.L. Prevention of heteroduplex formation in mRNA quantitation by reverse transcription-polymerase chain reaction. Anal. Biochem. 266 (1999) 230-232
5. Clarke D.C., Betterton M.D., and Liu X. Systems theory of Smad signalling. Syst. Biol. (Stevenage) 153 (2006) 412-424
6. Datto M.B., Frederick J.P., Pan L., Borton A.J., Zhuang Y., and Wang X.F. Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. Mol. Cell Biol. 19 (1999) 2495-2504
7. Dennler S., Huet S., and Gauthier J.M. A short amino-acid sequence in MH1 domain is responsible for functional differences between Smad2 and Smad3. Oncogene 18 (1999) 1643-1648
8. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 (2003) 577-584
9. Dunn N.R., Koonce C.H., Anderson D.C., Islam A., Bikoff E.K., and Robertson E.J. Mice exclusively expressing the short isoform of Smad2 develop normally and are viable and fertile. Genes Dev. 19 (2005) 152-163
10. Dunn N.R., Vincent S.D., Oxburgh L., Robertson E.J., and Bikoff E.K. Combinatorial activities of Smad2 and Smad3 regulate mesoderm formation and patterning in the mouse embryo. Development 131 (2004) 1717-1728
11. Eckhart L., Ban J., Ballaun C., Weninger W., and Tschachler E. Reverse transcription-polymerase chain reaction products of alternatively spliced mRNAs form DNA heteroduplexes and heteroduplex complexes. J. Biol. Chem. 274 (1999) 2613-2615
12. Garcia-Campmany L., and Marti E. The TGF{beta} intracellular effector Smad3 regulates neuronal differentiation and cell fate specification in the developing spinal cord. Development 134 (2007) 65-75
13. Grimm O.H., and Gurdon J.B. Nuclear exclusion of Smad2 is a mechanism leading to loss of competence. Nat. Cell Biol. 4 (2002) 519-522
14. Hansson E., and Rönnbäck L. Primary cultures of astroglia and neurons from different brain regions. In: Shahar A., DeVellis J., Vernadakis A., and Haber B. (Eds). A Dissection and Tissue Culture Manual of the Nervous System (1989), Alan R. Liss, New York 92-104
15. Itoh S., Itoh F., Goumans M.J., and ten Dijke P. Signaling of transforming growth factor-beta family members through Smad proteins. Eur. J. Biochem. 267 (2000) 6954-6967
16. Jonk L.J., Itoh S., Heldin C.H., ten Dijke P., and Kruijer W. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer. J. Biol. Chem. 273 (1998) 21145-21152
17. Ju W., Ogawa A., Heyer J., Nierhof D., Yu L., Kucherlapati R., Shafritz D.A., and Bottinger E.P. Deletion of Smad2 in mouse liver reveals novel functions in hepatocyte growth and differentiation. Mol. Cell Biol. 26 (2006) 654-667
18. Lee H.G., Ueda M., Zhu X., Perry G., and Smith M.A. Ectopic expression of phospho-Smad2 in Alzheimer's disease: uncoupling of the transforming growth factor-beta pathway?. J. Neurosci. Res. 84 (2006) 1856-1861
19. Lin A.H., Luo J., Mondshein L.H., ten Dijke P., Vivien D., Contag C.H., and Wyss-Coray T. Global analysis of Smad2/3-dependent TGF-beta signaling in living mice reveals prominent tissue-specific responses to injury. J. Immunol. 175 (2005) 547-554
20. Lu J., Wu Y., Sousa N., and Almeida O.F. SMAD pathway mediation of BDNF and TGFbeta2 regulation of proliferation and differentiation of hippocampal granule neurons. Development 132 (2005) 3231-3242
21. Luo J., Lin A.H., Masliah E., and Wyss-Coray T. Bioluminescence imaging of Smad signaling in living mice shows correlation with excitotoxic neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 18326-18331
22. Massague J., Seoane J., and Wotton D. Smad transcription factors. Genes Dev. 19 (2005) 2783-2810
23. Mukerji S.S., Katsman E.A., Wilber C., Haner N.A., Selman W.R., and Hall A.K. Activin is a neuronal survival factor that is rapidly increased after transient cerebral ischemia and hypoxia in mice. J. Cereb. Blood Flow Metab. 27 (2007) 1161-1172
24. Nomura M., and Li E. Smad2 role in mesoderm formation, left-right patterning and craniofacial development. Nature 393 (1998) 786-790
25. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
26. Shi Y., Wang Y.F., Jayaraman L., Yang H., Massague J., and Pavletich N.P. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 94 (1998) 585-594
27. Stegmuller J., Huynh M.A., Yuan Z., Konishi Y., and Bonni A. TGFbeta-Smad2 signaling regulates the Cdh1-APC/SnoN pathway of axonal morphogenesis. J. Neurosci. 28 (2008) 1961-1969
28. Takenoshita S., Mogi A., Nagashima M., Yang K., Yagi K., Hanyu A., Nagamachi Y., Miyazono K., and Hagiwara K. Characterization of the MADH2/Smad2 gene, a human Mad homolog responsible for the transforming growth factor-beta and activin signal transduction pathway. Genomics 48 (1998) 1-11
29. ten Dijke P., and Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem. Sci. 29 (2004) 265-273
30. Thompson J.R., Marcelino L.A., and Polz M.F. Heteroduplexes in mixed-template amplifications: formation, consequence and elimination by 'reconditioning PCR'. Nucleic Acids Res. 30 (2002) 2083-2088
31. Town T., Laouar Y., Pittenger C., Mori T., Szekely C.A., Tan J., Duman R.S., and Flavell R.A. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 14 (2008) 681-687
32. Tremblay K.D., Hoodless P.A., Bikoff E.K., and Robertson E.J. Formation of the definitive endoderm in mouse is a Smad2-dependent process. Development 127 (2000) 3079-3090
33. Ueberham U., Ueberham E., Gruschka H., and Arendt T. Altered subcellular location of phosphorylated Smads in Alzheimer's disease. Eur. J. Neurosci. 24 (2006) 2327-2334
34. van Grunsven L.A., Verstappen G., Huylebroeck D., and Verschueren K. Smads and chromatin modulation. Cytokine Growth Factor Rev. 16 (2005) 495-512
35. Volgin D.V., Swan J., and Kubin L. Single-cell RT-PCR gene expression profiling of acutely dissociated and immunocytochemically identified central neurons. J. Neurosci. Methods 136 (2004) 229-236
36. Weinstein M., Yang X., Li C., Xu X., Gotay J., and Deng C.X. Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 9378-9383
37. Yagi K., Goto D., Hamamoto T., Takenoshita S., Kato M., and Miyazono K. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J. Biol. Chem. 274 (1999) 703-709
38. Yang X., Letterio J.J., Lechleider R.J., Chen L., Hayman R., Gu H., Roberts A.B., and Deng C. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J. 18 (1999) 1280-1291
39. Zhu Y., Richardson J.A., Parada L.F., and Graff J.M. Smad3 mutant mice develop metastatic colorectal cancer. Cell 94 (1998) 703-714